- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00758862
The Pharmacokinetics of 2% TD1414 Cream in Adults With Secondarily Infected Traumatic Lesions (SITL) or Impetigo
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
College Station, Texas, United States, 77840
- J&S Studies, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ability and willingness to comply with all the study requirements/procedures
- Age ≥ 18 and ≤65 years
- Primary bullous/non-bullous impetigo or SITL
Patients suffering from primary bullous/non-bullous impetigo must have:
- Not more than 10 discrete lesions, and
- A total lesional area ≥ 1 cm2 and ≤ 100 cm2, and
- Any surrounding erythema must not extend beyond 2 cm from the edge of the lesion, and
- Total SIRS score equal to or ≥ 8
Patients suffering from SITL must have:
- A total infected area of the traumatic lesion ≥ 1 cm2 and ≤ 100 cm2, and
- Any surrounding erythema must not extend beyond 2 cm from the edge of the lesion, and
- Total SIRS score ≥ 8, and
- SITL not caused by burns or animal/human bite
- Amenable for treatment with topical antibiotic alone
- Body Mass Index ≥18 and ≤ 35 kg/m2.
Exclusion Criteria:
- Immunosuppressed state or other serious systemic disease
- Signs and/or symptoms of systemic infection, such as malaise and fever or local adenopathy and fever
- Unwillingness to abstain from use of any other topical products including emollients on the lesional area during the study
- Systemic treatment with antibacterials or immunosuppressive agents (e.g. corticosteroids) within 2 days before day 1 (inhaled/intranasal steroids may be used)
- Topical treatment with antibacterials, immunosuppressive agents (e.g. corticosteroids) or antiseptics (e.g. alcohol, chlorhexidine, hydrogen peroxide, iodine) on the lesional area within 2 days before day 1
- Indication for surgical or systemic treatment of the SITL/impetigo
- Known or suspected hypersensitivity to any of the components of the study medication
- Participation in any other interventional clinical trial or use of an investigational drug within 30 days or 5 half-lives (whichever is longer) prior to day 1
- Previously enrolled in this study
- A blood alcohol content ≥ 0.08% as determined by a Breathalyzer test
- Known or suspected history of alcohol abuse/alcoholism or drug abuse
- Known or suspected impairment of liver function
- Heart rhythm disturbances or clinically significant quantitative or qualitative abnormality in the pretreatment ECG
- Blood donation in excess of 500mL within 56 days before day 1 or donation during the study or within 3 days of leaving the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
|
Application 3 times daily for 7 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
TD1414 Serum Concentration by Timepoint
Time Frame: From 0 hours to 240 hours
|
On Days 1 and 2(and possibly Day 3 depending on the time of first application on Day 1) a sample was taken for pharmacokinetic(PK) analysis at any time before first application on Day 1, and at 12±1, 18±1, 24±1 and 36±4 hours after first application.
If the 36±4 hours sampling time fell on Day 3, then a second sample was also required on Day 3, but was to be obtained at 6pm or afterwards.
On Days 3 to 6(and also Day 7 if the very last application fell on Day 8), one sample was taken on each day at any time during the day.
On Days 7 and 8(or Days 8 and 9 if very last application was on Day 8), a sample was taken immediately before the very last application and at 6±1, 12±1 and 24±2 hours after the very last application.
On Days 9 and 10, one sample was taken on each day at any time during the day.
If the participant had already had a sample(s) taken on Day 9 because the timing of some of the post-last application samples fell on this day, then further samples were not required on Day 9
|
From 0 hours to 240 hours
|
Peak TD1414 Serum Concentration (Cmax )
Time Frame: From 0 hours to 240 hours
|
The Cmax was summarised by lesion size at baseline, by SIRS scores at baseline and by amount of TD1414 cream used. Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses. For description of lesion size, SIRS score and amount of TD1414 cream used please see outcome measure 3, 4 and 5 respectively. |
From 0 hours to 240 hours
|
Peak Serum Concentration by Baseline Lesion Size
Time Frame: From 0 hours to 240 hours
|
On Day 1 (before the first application), the (sub)investigator recorded the size of the lesion(s). For each participant the size of the lesion was allocated to one of two categories: ≤15cm² or >15cm². The Cmax is presented by baseline lesion size category (≤15 cm² and >15 cm²). Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses. |
From 0 hours to 240 hours
|
Peak Serum Concentration by SIRS Score
Time Frame: From 0 hours to 240 hours
|
On Day 1 (before the first application), the (sub)investigator recorded the severity of the lesion(s). The severity was to be recorded using the Severity of Infection Rating Scale (SIRS). For the SIRS, the following seven clinical signs/symptoms of infection were assessed: Exudates/pus Crusting Erythema Oedema Tissue warmth Itching Pain Each of the seven signs/symptoms was scored using the following scale: 0 = absent 2 = mild 4 = moderate 6 = severe The scores for each sign/symptom were summed to give the total SIRS score. The total SIRS score could range from 0 to 42. Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses. |
From 0 hours to 240 hours
|
Peak Serum Concentration by Amount of TD1414 Cream Used
Time Frame: From 0 hours to 240 hours
|
The weight of TD1414 cream used was calculated by subtracting the weight of the used dispensed tube from the mean weight of a full tube. Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses. |
From 0 hours to 240 hours
|
Time to Reach Peak Serum Concentration (Tmax )
Time Frame: From 0 hours to 240 hours
|
Please see 1.
Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.
|
From 0 hours to 240 hours
|
Time to Reach Peak Serum Concentration (Tmax ) by Baseline Lesion Size
Time Frame: From 0 hours to 240 hours
|
Please see 1.
Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.
|
From 0 hours to 240 hours
|
Time to Reach Peak Serum Concentration (Tmax ) by SIRS Score
Time Frame: From 0 hours to 240 hours
|
Please see 1.
Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.
|
From 0 hours to 240 hours
|
Time to Reach Peak Serum Concentration (Tmax ) by Amount of TD1414 Cream Used
Time Frame: From 0 hours to 240 hours
|
Please see 1.
Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses.
|
From 0 hours to 240 hours
|
Area Under the Curve (AUC(0-t))
Time Frame: From 0 hours to 240 hours
|
Area under the concentration-time curve (AUC(0-t)) from time 0 to time of last non-zero observation after dosing, calculated by linear/log trapezoidal method. Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses. |
From 0 hours to 240 hours
|
Area Under the Curve by Baseline Lesion Size
Time Frame: From 0 hours to 240 hours
|
On Day 1 (before the first application), the (sub)investigator recorded the size of the lesion(s). For each participant the size of the lesion was allocated to one of two categories: ≤15cm² or >15cm². Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses. |
From 0 hours to 240 hours
|
Area Under the Curve by SIRS Score
Time Frame: From 0 hours to 240 hours
|
On Day 1 (before the first application), the (sub)investigator recorded the severity of the lesion(s). The severity was to be recorded using the Severity of Infection Rating Scale (SIRS). For the SIRS, the following seven clinical signs/symptoms of infection were assessed: Exudates/pus, Crusting, Erythema, Oedema, Tissue warmth, Itching and Pain. Each of the seven signs/symptoms was scored using the following scale: 0 = absent 2 = mild 4 = moderate 6 = severe The scores for each sign/symptom were summed to give the total SIRS score. The total SIRS score could range from 0 to 42. Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses. |
From 0 hours to 240 hours
|
Area Under the Curve (AUC(0-t)) by Amount of TD1414 Cream Used
Time Frame: From 0 hours to 240 hours
|
The weight of TD1414 cream used was calculated by subtracting the weight of the used dispensed tube from the mean weight of a full tube. Please see 1. Primary Outcome for details on collection of blood samples for the Pharmacokinetic analyses. |
From 0 hours to 240 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TD1414-C22
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Impetigo
-
Lytix Biopharma ASCompletedNon-bullous ImpetigoDominican Republic
-
GlaxoSmithKlineCompletedImpetigoIndia, Mexico, Netherlands, Italy, Peru
-
Ferrer Internacional S.A.Completed
-
Philippine Dermatological SocietySt. Luke's Medical CenterUnknown
-
NovaBay Pharmaceuticals, Inc.Novum Pharmaceutical Research Services; International Dermatology Research,...Completed
-
NovaBay Pharmaceuticals, Inc.CompletedImpetigoUnited States, South Africa
-
UNION therapeuticsCompleted
-
Ferrer Internacional S.A.CompletedEfficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With ImpetigoImpetigoGermany, South Africa
Clinical Trials on 2% TD1414 Cream
-
LEO PharmaCompletedSecondarily Infected Traumatic Lesions | ImpetigoUnited States, South Africa
-
UNION therapeuticsCompletedAtopic DermatitisCanada
-
Betta Pharmaceuticals Co., Ltd.Quintiles, Inc.Completed
-
University of ParmaCompletedInflammatory Response | Endotoxemia | Oxidative Stress | Glucose, High BloodItaly
-
Taro Pharmaceuticals USACompleted
-
Jamaica Hospital Medical CenterJohnson & JohnsonUnknownTinea Pedis | Athlete's Foot | Foot Fungus | RingwormUnited States
-
LUTRONIC CorporationCompleted
-
GlaxoSmithKlineCompleted
-
Chulalongkorn UniversityNot yet recruiting
-
Merz North America, Inc.CompletedTinea CorporisUnited States, Dominican Republic, Honduras